Darren Foard

A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

Ashutosh Wechalekar, Stefan Schönland, Efstathios Kastritis et al. · Blood · 2013 · 516 citations

Medicine, Cardiology, Internal Medicine +6

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

Christopher P. Venner, Thirusha Lane, Darren Foard et al. · Blood · 2012 · 279 citations

Medicine, Pharmacology, Pharmacotherapy +6

A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib

Richa Manwani, Oliver Cohen, Faye Sharpley et al. · Blood · 2019 · 192 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +8

Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis

Oliver Cohen, Andreia Ismael, Babita Pawarova et al. · European Heart Journal · 2021 · 110 citations · Full text

Medicine, Internal Medicine, Systemic Pathology +4

A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis

Christopher P. Venner, Julian D. Gillmore, Sajitha Sachchithanantham et al. · Leukemia · 2014 · 97 citations

Medicine, Pharmacology, Pharmacotherapy +9